Get started
Author

Janakan Krishnarajah

Observed name: J. Krishnarajah
OpenAlex ID: A5078212479
Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies
2017 · Gautam Goel, Tim King, et al. · The Lancet. Gastroenterology & hepatology · 151
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers
2017 · Patrick F. Smith, Janakan Krishnarajah, et al. · British Journal of Clinical Pharmacology · 110
PDF
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults
2018 · Susan B. Manoff, Michele Sausser, et al. · Human Vaccines & Immunotherapeutics · 78
PDF
Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial
2015 · D. D. Kim, J. Krishnarajah, et al. · Diabetes Obesity and Metabolism · 63
Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?
2014 · Helen I Keen, Janakan Krishnarajah, et al. · Expert Opinion on Drug Safety · 41
Refined Localisation of the Genes for Nebulin and Titin on Chromosome 2q Allows the Assignment of Nebulin as a Candidate Gene for Autosomal Recessive Nemaline Myopathy
1997 · Katarina Pelin, Maaret Ridanpää, et al. · European Journal of Human Genetics · 37
The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine
2017 · Stephen Chin Beng Lim, Stephan Schug, et al. · Pain Medicine · 17
SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure
2015 · P.F. Smith, J. Krishnarajah, et al. · Annals of the Rheumatic Diseases · 9
Sa1396 A Single Intradermal (ID) Injection of Nexvax2®, a Peptide Composition With Dominant Epitopes for Gluten-Reactive CD4+ T Cells, Activates T Cells and Triggers Acute Gastrointestinal Symptoms in HLA-DQ2.5+ People With Celiac Disease (CeD)
2016 · Gautam Goel, Toufic Mayassi, et al. · Gastroenterology · 5
846 Efficacy, Safety, Tolerability, and Immunological Effects of Nexvax2®, a Peptide-Based Therapeutic Vaccine, Administered by Intra-Dermal (ID) Injection Twice-Weekly for 8-Weeks in HLA-DQ2.5+ Celiac Disease (CeD)
2016 · Gautam Goel, Tim King, et al. · Gastroenterology · 2
Sa1395 Nexvax2®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD)
2016 · Gautam Goel, Jane M. Andrews, et al. · Gastroenterology · 2
A Phase I Study of the Pharmacokinetics, Safety and Tolerability of a Novel Tocopheryl Phosphate Mixture/Oxymorphone Transdermal Patch System
2017 · Paul D Gavin, Lee S Simon, et al. · Pain Management · 1
(439) A transdermal oxymorphone patch delivers therapeutic plasma concentrations of oxymorphone: an open label Phase I clinical trial
2014 · P. Gavin, M. El-Tamimy, et al. · Journal of Pain
Quick turnaround vital for ethical human research
2014 · Peter J. Leedman, Janakan Krishnarajah
Works count: 14
Citation count: 516
H-index: 8
I10-index: 7
Year
Topic
Type